CN108271364A - 用于降解错误折叠的蛋白质的组合物和方法 - Google Patents

用于降解错误折叠的蛋白质的组合物和方法 Download PDF

Info

Publication number
CN108271364A
CN108271364A CN201680044063.4A CN201680044063A CN108271364A CN 108271364 A CN108271364 A CN 108271364A CN 201680044063 A CN201680044063 A CN 201680044063A CN 108271364 A CN108271364 A CN 108271364A
Authority
CN
China
Prior art keywords
pml
protein
disease
atxn1
proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680044063.4A
Other languages
English (en)
Chinese (zh)
Inventor
杨小鲁
郭骊骊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania Penn
Original Assignee
University of Pennsylvania Penn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pennsylvania Penn filed Critical University of Pennsylvania Penn
Publication of CN108271364A publication Critical patent/CN108271364A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
CN201680044063.4A 2015-05-29 2016-05-27 用于降解错误折叠的蛋白质的组合物和方法 Pending CN108271364A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562168309P 2015-05-29 2015-05-29
US62/168,309 2015-05-29
PCT/US2016/034751 WO2016196328A1 (en) 2015-05-29 2016-05-27 Compositions and methods for degradation of misfolded proteins

Publications (1)

Publication Number Publication Date
CN108271364A true CN108271364A (zh) 2018-07-10

Family

ID=57441753

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680044063.4A Pending CN108271364A (zh) 2015-05-29 2016-05-27 用于降解错误折叠的蛋白质的组合物和方法

Country Status (15)

Country Link
US (2) US11542500B2 (https=)
EP (1) EP3302706A4 (https=)
JP (3) JP7011467B2 (https=)
KR (2) KR20240108531A (https=)
CN (1) CN108271364A (https=)
AU (3) AU2016271635B2 (https=)
BR (1) BR112017025574A2 (https=)
CA (1) CA2987057A1 (https=)
HK (1) HK1252757A1 (https=)
IL (3) IL255912B2 (https=)
MX (3) MX2017015373A (https=)
RU (2) RU2021134920A (https=)
SG (1) SG10202011833TA (https=)
WO (1) WO2016196328A1 (https=)
ZA (1) ZA201708067B (https=)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110302383A (zh) * 2019-07-29 2019-10-08 深圳先进技术研究院 Trim11基因和蛋白靶点以及抑制剂在乳腺癌中的用途
CN110669791A (zh) * 2019-10-29 2020-01-10 成都益安博生物技术有限公司 一种提高细胞抗体表达量的方法
CN113292658A (zh) * 2021-04-17 2021-08-24 复旦大学 一种融合蛋白及其在靶向降解细胞内蛋白中的应用
CN113651879A (zh) * 2021-08-18 2021-11-16 武汉华美生物工程有限公司 一种trim21全长蛋白的制备方法及应用
CN117159747A (zh) * 2023-08-30 2023-12-05 暨南大学 一种亨廷顿舞蹈症的药物及其制备方法
CN120209082A (zh) * 2025-05-28 2025-06-27 中南大学 一种靶向阻断trim25与brd7蛋白结合的多肽及其应用

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201703148TA (en) 2014-11-05 2017-05-30 Voyager Therapeutics Inc Aadc polynucleotides for the treatment of parkinson's disease
CA3193811A1 (en) 2014-11-14 2016-05-19 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (als)
CN119876138A (zh) 2014-11-14 2025-04-25 沃雅戈治疗公司 调节性多核苷酸
CA3024448C (en) 2016-05-18 2025-09-09 Voyager Therapeutics, Inc. MODULATING POLYNUCLEOTIDES
CN110753557B (zh) * 2017-03-22 2024-03-22 神济昌华(北京)生物科技有限公司 Trim72通过泛素化fus蛋白突变体作为als的潜在治疗性靶标
EP3618839A4 (en) 2017-05-05 2021-06-09 Voyager Therapeutics, Inc. COMPOSITIONS AND METHODS OF TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
CN109609614B (zh) * 2017-09-30 2022-07-15 首都医科大学附属北京胸科医院 检测trim2、trim4、trim32和/或trim46基因或蛋白产品的用途
WO2019079242A1 (en) 2017-10-16 2019-04-25 Voyager Therapeutics, Inc. TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
TW202413649A (zh) 2017-10-16 2024-04-01 美商航海家醫療公司 肌萎縮性脊髓側索硬化症(als)之治療
CN108018303A (zh) * 2017-12-20 2018-05-11 江苏浩欧博生物医药股份有限公司 一种人Ro52重组蛋白的制备方法
WO2019175881A1 (en) 2018-03-14 2019-09-19 Technion Research & Development Foundation Limited A prognostic biomarker in cancer
SG11202011296VA (en) 2018-05-15 2020-12-30 Voyager Therapeutics Inc Compositions and methods for the treatment of parkinson's disease
US11147815B2 (en) 2018-08-21 2021-10-19 Synkrino Biotherapeutics, Inc. Compositions and methods for treating diseases associated with uncontrolled inflammatory responses
EP3863642A4 (en) * 2018-10-09 2022-06-29 The Regents of the University of California Covalent targeting of e3 ligases
WO2020227515A1 (en) * 2019-05-07 2020-11-12 Voyager Therapeutics, Inc. Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
KR102114880B1 (ko) * 2020-01-15 2020-05-26 서울대학교병원 코돈 최적화된 TIF1γ 폴리뉴클레오티드를 포함하는 재조합 벡터 및 이의 용도
GB202005876D0 (en) * 2020-04-22 2020-06-03 Univ Dundee Protein degradation
WO2022165313A1 (en) 2021-02-01 2022-08-04 Regenxbio Inc. Gene therapy for neuronal ceroid lipofuscinoses
CN118272444A (zh) * 2024-02-29 2024-07-02 宜昌市中心人民医院(三峡大学第一临床医学院、三峡大学附属中心人民医院) 一种慢病毒载体LV-Trim69及其在制备改善心脏衰老药物上的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100129438A1 (en) * 2004-02-25 2010-05-27 Dana-Farber Cancer Institute, Inc. Methods and Compositions for the Treatment and Prevention of HIV Infection Using TRIM5ALPHA
CN103127492A (zh) * 2011-11-23 2013-06-05 中国科学院上海巴斯德研究所 一种抗丙型肝炎病毒的蛋白及其用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010027182A1 (en) * 1998-05-29 2001-10-04 Huda Y. Zoghbi Chaperone suppression of ataxin-1 aggregation and altered subcellular proteasome localization imply protein misfilind in sca1
WO2001090342A2 (en) 2000-05-22 2001-11-29 Johns Hopkins University Genetic engineering of vascular grafts to resist disease
US20040235733A1 (en) * 2003-02-27 2004-11-25 Steffan Joan S. Methods and reagents for reducing polyglutamine toxicity
US20050215562A1 (en) * 2003-06-23 2005-09-29 Patrick Tremblay Methods for treating protein aggregation disorders
US20140056873A1 (en) 2004-06-10 2014-02-27 University Of Leicester Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
WO2006116716A2 (en) * 2005-04-27 2006-11-02 University Of Florida Materials and methods for enhanced degradation of mutant proteins associated with human disease
EP1870107A1 (en) * 2006-06-23 2007-12-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of inducer of promyelocytic leukemia protein (PML) for treating polyglutamine expansion neurodegenerative diseases
US7785857B2 (en) 2006-08-31 2010-08-31 Saint Louis University Protein C variant
CA2749163A1 (en) 2009-01-14 2010-07-22 The Salk Institute For Biological Studies Methods for screening and compounds that protect against amyloid diseases
EP2826860B1 (en) * 2010-04-23 2018-08-22 University of Massachusetts CNS targeting AAV vectors and methods of use thereof
GB201012410D0 (en) * 2010-07-23 2010-09-08 Medical Res Council Intracellular immunity
AU2011295629B2 (en) 2010-09-01 2014-05-01 Organ Transport Pty Ltd Perfusion composition
TR201905612T4 (tr) * 2012-12-05 2019-05-21 Univ Heidelberg Ruprecht Karls Proteinlerin ve çok değerlikli, hücreye nüfuz eden peptitlerin konjugatları ve bunların kullanımları.
US20160136123A1 (en) * 2013-06-14 2016-05-19 Vojo P. Deretic Treatment of autophagy-related disorders
WO2016054554A1 (en) * 2014-10-03 2016-04-07 University Of Massachusetts Heterologous targeting peptide grafted aavs

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100129438A1 (en) * 2004-02-25 2010-05-27 Dana-Farber Cancer Institute, Inc. Methods and Compositions for the Treatment and Prevention of HIV Infection Using TRIM5ALPHA
CN103127492A (zh) * 2011-11-23 2013-06-05 中国科学院上海巴斯德研究所 一种抗丙型肝炎病毒的蛋白及其用途

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
PRADEEP D. UCHIL等: "TRIM E3 Ligases Interfere with Early and Late Stages of the Retroviral Life Cycle", 《PLOS PATHOGENS》 *
TAKAKO NIIKURA等: "A tripartite motif protein TRIM11 binds and destabilizes Humanin, a neuroprotective peptide against Alzheimer"s disease-relevant insults", 《EUROPEAN JOURNAL OF NEUROSCIENCE》 *
TRAN CONG TUOC等: "Trim11 modulates the function of neurogenic transcription factor Pax6 through ubiquitin–proteosome system", 《GENES & DEVELOPMENT》 *
王晔等: "蛋白质错误折叠与神经退行性疾病", 《中国临床神经科学》 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110302383A (zh) * 2019-07-29 2019-10-08 深圳先进技术研究院 Trim11基因和蛋白靶点以及抑制剂在乳腺癌中的用途
CN110669791A (zh) * 2019-10-29 2020-01-10 成都益安博生物技术有限公司 一种提高细胞抗体表达量的方法
CN113292658A (zh) * 2021-04-17 2021-08-24 复旦大学 一种融合蛋白及其在靶向降解细胞内蛋白中的应用
CN113292658B (zh) * 2021-04-17 2023-02-28 复旦大学 一种融合蛋白及其在靶向降解细胞内蛋白中的应用
CN113651879A (zh) * 2021-08-18 2021-11-16 武汉华美生物工程有限公司 一种trim21全长蛋白的制备方法及应用
CN117159747A (zh) * 2023-08-30 2023-12-05 暨南大学 一种亨廷顿舞蹈症的药物及其制备方法
CN117159747B (zh) * 2023-08-30 2024-12-20 暨南大学 一种亨廷顿舞蹈症的药物及其制备方法
CN120209082A (zh) * 2025-05-28 2025-06-27 中南大学 一种靶向阻断trim25与brd7蛋白结合的多肽及其应用
CN120209082B (zh) * 2025-05-28 2025-08-05 中南大学 一种靶向阻断trim25与brd7蛋白结合的多肽及其应用

Also Published As

Publication number Publication date
JP2024161501A (ja) 2024-11-19
RU2017144862A (ru) 2019-07-02
RU2761564C2 (ru) 2021-12-10
US20180163202A1 (en) 2018-06-14
US11542500B2 (en) 2023-01-03
RU2017144862A3 (https=) 2019-11-20
IL302965B1 (en) 2025-08-01
MX2024001616A (es) 2024-02-28
RU2761564C9 (ru) 2022-03-17
KR20240108531A (ko) 2024-07-09
IL322085A (en) 2025-09-01
RU2021134920A (ru) 2022-04-15
BR112017025574A2 (en) 2018-08-14
AU2022200673A1 (en) 2022-02-24
JP2018521014A (ja) 2018-08-02
IL302965B2 (en) 2025-12-01
IL302965A (en) 2023-07-01
ZA201708067B (en) 2018-11-28
IL255912B1 (en) 2023-06-01
KR20180011276A (ko) 2018-01-31
AU2025230665A1 (en) 2025-10-02
MX2021014954A (es) 2022-01-31
CA2987057A1 (en) 2016-12-08
JP2022000459A (ja) 2022-01-04
JP7011467B2 (ja) 2022-02-10
EP3302706A1 (en) 2018-04-11
US20230313190A1 (en) 2023-10-05
WO2016196328A1 (en) 2016-12-08
EP3302706A4 (en) 2019-05-08
AU2016271635A1 (en) 2018-01-25
MX2017015373A (es) 2018-07-06
SG10202011833TA (en) 2021-01-28
AU2022200673B2 (en) 2025-06-05
IL255912B2 (en) 2023-10-01
HK1252757A1 (zh) 2019-05-31
IL255912A (en) 2018-01-31
AU2016271635B2 (en) 2021-11-04

Similar Documents

Publication Publication Date Title
AU2022200673B2 (en) Compositions and methods for degradation of misfolded proteins
KR100607612B1 (ko) 종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물
AU776672B2 (en) Characterization of a calcium channel family
US12473334B2 (en) SWI/SNF family chromatin remodeling complexes and uses thereof
US6262333B1 (en) Human genes and gene expression products
US20040115629A1 (en) Molecules for diagnostics and therapeutics
US20250283871A1 (en) Compositions and methods for modulating the interaction between ss18-ssx fusion oncoprotein and nucleosomes
KR20120082906A (ko) 자가포식현상-향상 유전자 생성물의 조절을 통한 자가포식현상의 조절 방법
KR20220044811A (ko) Crispr/cas13을 사용하는 표적화된 트랜스-이어맞추기
KR20070100235A (ko) 종양의 진단 및 치료를 위한 조성물 및 방법
US20040053262A1 (en) Supressor gene
KR20060015296A (ko) 신경교 기원의 종양의 진단 및 치료를 위한 조성물 및 방법
JP2012065671A (ja) Ｍａｃａｃａｆａｓｃｉｃｕｌａｒｉｓ由来のＰ−糖タンパク質およびその使用
US20040146971A1 (en) Novel p53 inducible protein
US20240115671A1 (en) Intracellular delivery of therapeutic proteins designed to invade and autonomously lyse and methods of use thereof
US6235879B1 (en) Apoptosis modulators that interact with the Huntington's disease gene
US12478665B2 (en) Cancer vaccine compositions and methods for using same to prevent and/or treat cancer
US6171857B1 (en) Leucine zipper protein, KARP-1 and methods of regulating DNA dependent protein kinase activity
US6753177B1 (en) P-glycoproteins and uses thereof
EP1220911B1 (en) P-glycoproteins and uses thereof
EP1428891A1 (en) Novel gene nedl-1
KR100515859B1 (ko) 신규 폴리펩티드 및 이를 코딩하는 핵산
JP2001521392A (ja) 新規なヒト腫瘍抑制遺伝子
JP4280878B2 (ja) Ｍａｓｌ１遺伝子
US20050089858A1 (en) Salvador tumor suppressor gene

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination